CTOs on the Move

Continucare Corporation

www.continucare.com

 
Continucare Corporation is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Continucare Corporation is based in Miami, FL. You can find more information on Continucare Corporation at www.continucare.com
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Independence Blue Cross

Proudly celebrating its 75th anniversary in 2013, Independence Blue Cross is the leading health insurer in southeastern Pennsylvania. With our affiliates, we have 3.1 million members nationwide. We are enhancing the health and wellness of the people and communities we serve by delivering innovative and competitively priced health care products and services; pioneering new ways to reward doctors, hospitals, and other health care professionals for coordinated, quality care; and supporting programs and events that promote wellness.

HydroJug

The Best Insulated Gallon Water Bottle. Portable, Convenient, 64 oz Water Jug With Straw And Carrying Sleeve. Glass, Stainless Steel, BPA Free. Easily Drink A Gallon A Day. Big Plastic And Metal Waterbottles.

Partners in Healthcare

Partners in Healthcare is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CLMBR

A machine built to move with you. CLMBR offers a unique combination of high intensity cardio, resistance strength training, and connected technology.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.